Linked Life Data

16001952

Source:http://linkedlifedata.com/resource/pubmed/id/16001952

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2005-7-8
pubmed:abstractText
Fulvestrant is a new type of estrogen receptor antagonist with no agonist effects, and represents a valuable addition to the range of endocrine treatments available to treat postmenopausal women with advanced breast cancer. Fulvestrant binds, blocks and degrades the estrogen receptor, thereby retarding growth and progression of hormone-sensitive tumors. Two Phase III trials have demonstrated that fulvestrant is at least as effective as the third-generation aromatase inhibitor anastrozole in the treatment of advanced breast cancer following progression on antiestrogen therapy. In addition, a Phase III trial comparing fulvestrant with tamoxifen in postmenopausal women with advanced breast cancer showed similar efficacy and tolerability. Clinical trials are ongoing to evaluate different endocrine sequence options for postmenopausal women with breast cancer, and to evaluate the efficacy of fulvestrant in combination with anticancer agents that target other signaling pathways.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1744-8328
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
445-53
pubmed:dateRevised
2007-12-5
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
pubmed:affiliation
Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine, The Robert H Lurie Comprehensive Cancer Center, Northwestern University, 676 North St Claire, Chicago, IL 60611, USA. w-gradishar@northwestern.edu
pubmed:publicationType
Journal Article, Review